HK1104035A1 - Crystalline esomeprazole strontium hydrate, method for preparing the same and pharmaceutical composition containing the same - Google Patents

Crystalline esomeprazole strontium hydrate, method for preparing the same and pharmaceutical composition containing the same

Info

Publication number
HK1104035A1
HK1104035A1 HK07108597.3A HK07108597A HK1104035A1 HK 1104035 A1 HK1104035 A1 HK 1104035A1 HK 07108597 A HK07108597 A HK 07108597A HK 1104035 A1 HK1104035 A1 HK 1104035A1
Authority
HK
Hong Kong
Prior art keywords
same
pharmaceutical composition
composition containing
preparing
strontium hydrate
Prior art date
Application number
HK07108597.3A
Inventor
Tae Hee Ha
Hee Sook Oh
Won Jeoung Kim
Chang Hee Park
Eun Young Kim
Young Hoon Kim
Kwee Hyun Suh
Gwan Sun Lee
Original Assignee
Hanmi Science Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Science Co Ltd filed Critical Hanmi Science Co Ltd
Publication of HK1104035A1 publication Critical patent/HK1104035A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

This invention provides a crystalline S-omeprazole strontium hydrate for the prevention or treatment of gastric acid-related diseases, which has high optical purity, theremostability, solubility and nonhygroscopicity, a method for preparing same, and a pharmaceutical composition containing same.
HK07108597.3A 2005-10-26 2007-08-07 Crystalline esomeprazole strontium hydrate, method for preparing the same and pharmaceutical composition containing the same HK1104035A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20050101059 2005-10-26

Publications (1)

Publication Number Publication Date
HK1104035A1 true HK1104035A1 (en) 2008-01-04

Family

ID=37872502

Family Applications (1)

Application Number Title Priority Date Filing Date
HK07108597.3A HK1104035A1 (en) 2005-10-26 2007-08-07 Crystalline esomeprazole strontium hydrate, method for preparing the same and pharmaceutical composition containing the same

Country Status (10)

Country Link
US (4) US7576219B2 (en)
EP (2) EP1780207B1 (en)
KR (2) KR100818753B1 (en)
CN (1) CN101296921B (en)
BR (1) BRPI0617879A2 (en)
ES (1) ES2390848T3 (en)
HK (1) HK1104035A1 (en)
NZ (1) NZ568412A (en)
UA (1) UA86335C2 (en)
ZA (1) ZA200804492B (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7576219B2 (en) * 2005-10-26 2009-08-18 Hanmi Pharm. Co., Ltd Crystalline S-omeprazole strontium hydrate, method for preparing same, and pharmaceutical composition containing same
WO2009074997A2 (en) * 2007-12-10 2009-06-18 Lee Pharma Ltd. A novel process for the preparation of crystalline magnesium salt of (s)-omeprazole di hydrate
CN102887885B (en) * 2012-09-26 2014-12-10 江苏正大丰海制药有限公司 Preparation method of esomeprazole sodium
CN102964335B (en) * 2012-11-13 2014-06-25 凌元敏 Esomeprazole sodium compound and preparation method and applications thereof
CN103044400A (en) * 2012-12-21 2013-04-17 北京华禧联合科技发展有限公司 Esomeprazole magnesium salt and preparation method thereof
CN105853419B (en) * 2016-06-10 2018-11-20 江苏食品药品职业技术学院 A kind of pharmaceutical composition and its application for gastric ulcer treatment
CN107773529B (en) * 2016-08-24 2020-06-16 华仁药业股份有限公司 Esomeprazole sodium and sodium chloride injection and preparation method thereof
CN110526899A (en) * 2018-05-24 2019-12-03 刘力 Esomeprazole strontium noval chemical compound and its pharmaceutical composition and purposes
KR102197144B1 (en) 2019-03-29 2021-01-05 유한회사 더프라임솔루션 System of arcing prevention for Non-Thermal Plasma device of particulate matter reduction in exhaust gas
KR102249552B1 (en) 2020-06-16 2021-05-12 (주)에미션컨트롤스탠다드 Non-Thermal Plasma device for pollutants removal in ambient air and in exhaust gas

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (en) 1978-04-14 1979-10-15 Haessle Ab Gastric acid secretion
SE8301182D0 (en) 1983-03-04 1983-03-04 Haessle Ab NOVEL COMPOUNDS
DE4035455A1 (en) 1990-11-08 1992-05-14 Byk Gulden Lomberg Chem Fab ENANTIOMER SEPARATION
US5877192A (en) * 1993-05-28 1999-03-02 Astra Aktiebolag Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole
SE9301830D0 (en) 1993-05-28 1993-05-28 Ab Astra NEW COMPOUNDS
US6875872B1 (en) * 1993-05-28 2005-04-05 Astrazeneca Compounds
SE510666C2 (en) 1996-12-20 1999-06-14 Astra Ab New Crystal Modifications
SE510650C2 (en) 1997-05-30 1999-06-14 Astra Ab New association
SE9900274D0 (en) 1999-01-28 1999-01-28 Astra Ab New compound
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
WO2003074514A1 (en) 2002-03-05 2003-09-12 Astrazeneca Ab Alkylammonium salts of omeprazole and esomeprazole
WO2004099182A1 (en) 2003-05-05 2004-11-18 Ranbaxy Laboratories Limited Zinc salt of (s)-omeprazole
ATE386522T1 (en) 2003-07-23 2008-03-15 Nycomed Gmbh ALKALINE SALTS OF PROTON PUMP INHIBITORS
SE0302381D0 (en) 2003-09-04 2003-09-04 Astrazeneca Ab New salts I
SE0302382D0 (en) 2003-09-04 2003-09-04 Astrazeneca Ab New salts II
KR100598261B1 (en) 2003-12-30 2006-07-07 동부일렉트로닉스 주식회사 Apparatus for focucing wafer's contour in a stepper
RU2007145207A (en) 2005-05-06 2009-06-20 Гленмарк Фармасьютикалз Лимитед (In) ESOMEPRAZOL STRONGTED SALT, METHOD FOR PRODUCING IT AND CONTAINING ITS PHARMACEUTICAL COMPOSITIONS
US7576219B2 (en) * 2005-10-26 2009-08-18 Hanmi Pharm. Co., Ltd Crystalline S-omeprazole strontium hydrate, method for preparing same, and pharmaceutical composition containing same
RU2372345C1 (en) 2005-10-26 2009-11-10 Ханми Фарм. Ко., Лтд. S-omeprazole strontium salt or hydrate thereof, method of preparing said compounds and pharmaceutical composition containing said compounds

Also Published As

Publication number Publication date
EP1780207A2 (en) 2007-05-02
EP2269999B1 (en) 2016-03-02
BRPI0617879A2 (en) 2011-08-09
US20130303772A1 (en) 2013-11-14
EP2269999A1 (en) 2011-01-05
KR100818753B1 (en) 2008-04-01
US20070093533A1 (en) 2007-04-26
US8106076B2 (en) 2012-01-31
US7576219B2 (en) 2009-08-18
KR20080015483A (en) 2008-02-19
US8586752B1 (en) 2013-11-19
UA86335C2 (en) 2009-04-10
CN101296921B (en) 2012-07-18
CN101296921A (en) 2008-10-29
EP1780207A3 (en) 2007-07-04
US20110046383A1 (en) 2011-02-24
KR20070045101A (en) 2007-05-02
EP1780207B1 (en) 2012-08-15
ES2390848T3 (en) 2012-11-19
US8513426B2 (en) 2013-08-20
NZ568412A (en) 2010-11-26
US20090258908A1 (en) 2009-10-15
ZA200804492B (en) 2009-08-26

Similar Documents

Publication Publication Date Title
HK1104035A1 (en) Crystalline esomeprazole strontium hydrate, method for preparing the same and pharmaceutical composition containing the same
WO2006104826A3 (en) Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2007087548A3 (en) Chemical compounds
DK1855677T3 (en) 3.11 B-CIS dihydrotetrabenzene for the treatment of schizophrenia and other psychoses
EE04279B1 (en) Crystalline form of omeprazole
WO2007111864A3 (en) Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2007136577A3 (en) Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
TN2009000111A1 (en) Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2006057922A3 (en) Niacin receptor agonists, compositions containing such compounds and methods of treatment
ATE504570T1 (en) TARTRATE SALT FROM ISOFAGOMIN AND METHOD OF USE THEREOF
WO2007120575A3 (en) Niacin receptor agonists, compositions containing such compounds and methods of treatment
MX2009006529A (en) Crystalline forms of solvated ilaprazole.
WO2008051403A3 (en) Niacin receptor agonists, compositions containing such compounds and methods of treatment
PL2229938T3 (en) Ezetimibe compositions
WO2007109799A3 (en) Polymorphs of eszopiclone malate
WO2007075749A3 (en) Niacin receptor agonists, compositions containing such compounds and methods of treatment
WO2009121535A3 (en) Antiproliferative compounds and therapeutic uses thereof
WO2007129066A8 (en) 4- (2,6-dichloro-benzoylamino) -1h-pyrazole-3-carboxylic acid (1-methanesulphonyl-piperidin-4-yl) -amide for the treatment of cancer
NO20080037L (en) Combination of Pyrimidylaminobenzamide Compounds and Imatinib for the Treatment or Prevention of Proliferative Diseases
MY140986A (en) S-omeprazole strontium or hydrate thereof, method for preparing same, and pharmaceutical composition comprising same
PT1720867E (en) Process for the preparation of ziprasidone
WO2008011539A3 (en) Anesthetic compounds
WO2004055001A3 (en) Rabeprazole calcium
MXPA05009183A (en) Polymorphs of s-omeprazole.
TW200637867A (en) Cefcapene pivoxil methanesulfonic acid salt

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20170628